Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study Between AVP-923/AVP-786 and Itraconazole in Healthy Subjects
NCT02402595Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dextromethorphan + quinidine and deudextromethorphan (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change in plasma concentration of AVP-923 at 16 Days and Change in plasma concentration of AVP-786 at 16 Days. Started Mar 2015; status: completed.
02
Drugs
dextromethorphan + quinidinedeudextromethorphan
Beyond the preview
Go deeper on NCT02402595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402595.